Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
An erratum to this article was published (Cardiovasc Diabetol, 1 Jun 2024 ↗)
Pooled result · All-cause mortalityResult — go to the resultOdds ratio 0.49 95% CI 0.41–0.60Authors' conclusion
This systematic review and meta-analysis based on real-world data suggests that the combination of SGLT2is + GLP-1RAs is associated with lower all-cause mortality and favorable improvements in cardiovascular, renal, and glycemic measurements. The findings drive a call-to-action to incorporate this combination early and simultaneously in managing T2DM patients and achieve potential cardiovascular benefits and renal protection.
Study context
- Population
- Patients with T2D in a real-world setting13 studies
- Comparison
- SGLT2i + GLP-1 RA combination vs individual therapies
- Outcome
- All-cause mortality
Methodological detailsreal-world data, Searches of PubMed/MEDLINE, PROQuest, Scopus, CINAHL and Google Scholar; 1445 articles screened
- Real-world data
- Searches of PubMed/MEDLINE, PROQuest, Scopus, CINAHL and Google Scholar; 1445 articles screened
Pooled result
As reported in the abstract
Odds ratio
0.49
95% CI 0.41–0.60
P < 0.00001
Further pooled results
Effects of simultaneous administration of the combination
- Body mass index (BMI) reduction (p = 0.001)
- - 1.71 [- 2.74, - 0.67]
- Systolic blood pressure (SBP) reduction (p = 0.001)
- - 6.35 [- 10.17, - 2.53]
- HbA1c reduction (p < 0.00001)
- - 1.48 [- 1.75, - 1.21]
- Fasting plasma glucose (FPG) reduction (p < 0.00001)
- - 2.27 [- 2.78, - 1.76]
Total cholesterol
- Changes in total cholesterol and differences between simultaneous and sequential combination therapies were not significant
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →